PPARγ Regulates Triclosan Induced Placental Dysfunction

Area of Science:

• Reproductive toxicology
• Developmental biology
• Molecular endocrinology

Background:

• Triclosan (TCS) exposure is linked to adverse pregnancy outcomes.
• Peroxisome proliferator-activated receptor γ (PPARγ) plays a vital role in placental development.
• The protective mechanism of PPARγ against TCS-induced placental injury is not fully understood.

Purpose of the Study:

• To investigate the role of PPARγ in triclosan (TCS)-induced placental dysfunction.
• To elucidate the molecular mechanisms underlying PPARγ's protective effects against TCS toxicity.
• To evaluate the therapeutic potential of PPARγ activation in mitigating TCS-induced adverse effects.

Main Methods:

• In vitro studies using HTR-8/SVneo and JEG-3 cells to assess TCS effects on cell viability, migration, and angiogenesis.
• In vivo studies in mice to evaluate placental and fetal development following TCS exposure.
• Gene expression analysis of PPARγ and related inflammatory and angiogenesis markers.
• Pharmacological manipulation of PPARγ activity using agonists (rosiglitazone) and antagonists (GW9662).

Main Results:

• TCS inhibited cell viability, migration, and angiogenesis in placental cells in a dose-dependent manner.
• TCS downregulated PPARγ expression and its downstream genes while upregulating inflammatory markers.
• PPARγ activation (rosiglitazone) ameliorated TCS-induced cellular damage and inflammation.
• PPARγ inhibition (GW9662) exacerbated TCS toxicity.
• TCS exposure led to decreased placental and fetal weight in mice, which was alleviated by rosiglitazone treatment.

Conclusions:

• Triclosan (TCS) induces placenta and fetal developmental toxicity mediated by the PPARγ pathway.
• PPARγ acts as a protective factor against TCS-induced placental injury.
• Activation of PPARγ presents a potential therapeutic strategy to counteract the adverse effects of TCS exposure during pregnancy.